MedTrace Logo

A Pilot Bioavailability Study of 3 Test Tablet Formulations of Bazedoxifene Compared With A Reference Tablet Formulation of Bazedoxifene/Conjugated Estrogens in Healthy Postmenopausal Women

NCT01634789 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2013-01-18

No results posted yet for this study

Summary

The purpose of this study is to evaluate 3 test formulations relative to a reference formulation.

Conditions

  • Healthy

Interventions

DRUG

bazedoxifene

20 mg oral tablet, single dose

DRUG

bazedoxifene

20 mg oral tablet, single dose

DRUG

bazedoxifene

20 mg oral tablet, single dose

DRUG

bazedoxifene/conjugated estrogens

20 mg / 0.625 mg oral tablet, single dose

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
45 Years
Max Age
64 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-08-31
Primary Completion
2012-11-30
Completion
2012-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01634789 on ClinicalTrials.gov